Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:17 AM
Ignite Modification Date:
2025-12-25 @ 2:17 AM
NCT ID:
NCT07013760
Eligibility Criteria:
Inclusion Criteria:
Patients who received at least 1 tezepelumab dose after commercialization in Spain diagnosed with severe asthma who are inadequately controlled with high-dose inhaled corticosteroids and a long-acting β2-agonist ± additional medications for asthma control.
* Patients aged ≥12 years at the index date.
* Patients with continuous enrolment in the data source for at least 12-months before the index date.
* Patients with at least three months of continuous enrolment in the data source after the index date.
Exclusion Criteria:
Patients who received tezepelumab or any biologic drug for the treatment of asthma in a clinical trial at any time during the 12-months prior to the index date\*.
• Patients who had initiated 3 or more non-tezepelumab biologic treatment (omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab) for severe asthma at any time prior to the index date).
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
12 Years
Maximum Age:
105 Years
Study:
NCT07013760
Study Brief:
Protocol Section:
NCT07013760